Continuous positive airway pressure in COVID-19 patients with moderate-to-severe respiratory failure

Eur Respir J. 2021 Feb 17;57(2):2002524. doi: 10.1183/13993003.02524-2020. Print 2021 Feb.

Abstract

CPAP can be successfully used in a number of COVID-19 patients with hypoxaemic respiratory failure and gas exchange and radiological findings similar to those generally considered to be indications for invasive mechanical ventilation https://bit.ly/2GpBx6a

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Air Filters
  • Algorithms
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antirheumatic Agents / therapeutic use
  • COVID-19 / diagnostic imaging
  • COVID-19 / epidemiology
  • COVID-19 / physiopathology
  • COVID-19 / therapy*
  • COVID-19 Drug Treatment
  • Comorbidity
  • Continuous Positive Airway Pressure / methods*
  • Diabetes Mellitus / epidemiology
  • Female
  • Glucocorticoids / therapeutic use
  • Humans
  • Hydroxychloroquine / therapeutic use
  • Hypertension / epidemiology
  • Hypoxia / physiopathology
  • Hypoxia / therapy*
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use
  • Intubation, Intratracheal
  • Lung / diagnostic imaging
  • Male
  • Methylprednisolone / therapeutic use
  • Middle Aged
  • Noninvasive Ventilation / methods*
  • Oxygen Inhalation Therapy
  • Partial Pressure
  • Pulmonary Disease, Chronic Obstructive / epidemiology
  • Respiratory Insufficiency / diagnostic imaging
  • Respiratory Insufficiency / physiopathology
  • Respiratory Insufficiency / therapy*
  • SARS-CoV-2
  • Severity of Illness Index
  • Sex Factors
  • Tomography, X-Ray Computed
  • Treatment Failure
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Glucocorticoids
  • Interleukin 1 Receptor Antagonist Protein
  • Hydroxychloroquine
  • tocilizumab
  • Methylprednisolone